Report Follows Shady Arc of Diabetes Diagnostic Criteria and Drug Approval

If you were told that the American Diabetes Association (ADA) or the American Association of Clinical Endocrinologists (AACE) convened a panel of expert diabetes doctors in order to establish new definitions for things like pre-diabetes, or in order to update standard treatment guidelines for people with diabetes to reflect the very latest in advances, you would probably be encouraged.

Don't be.

A joint investigation by MedPage Today and the Milwaukee Journal Sentinel found that drug companies have been paying members of panels like these millions of dollars in speaking and consulting fees. These same companies have been frantically mixing up new concoctions to bring to market for the treatment of people with type 2 diabetes, and by lowering the threshold for what qualifies as diabetic or pre-diabetic these experts have been systematically creating a massive patient population to become consumers of these new and expensive drugs.

The result has been a massive $23 billion diabetes economy, and a betrayal of the trust patients put into physicians every day, in clinical settings all over the world.

The Payments

In order to determine which of these influential physicians were receiving payments by drug companies, MedPage Today and the Milwaukee Journal Sentinel used data provided by disclosures published by Eli Lilly, GlaxoSmithKlein and Merck, which only go as far back as 2009. The also used data provided by Medicare's Open Payments program, which only provides data covering the last five months of 2003.

Despite having a very narrow window to work from, investigators found that AACE panel members received $2.208 million in payments from drug companies, with the most coming from Merck—$735,367. Meanwhile, ADA panel members were paid $636,000 in the same time frame, with the most coming from Eli Lilly and Co—$312,754.

The Influential Panel Recommendations

When ADA or AACE panels like these meet, they discuss things like, should we re-evaluate the criteria used in order to determine whether a person can be diagnosed as having diabetes? You might think that such criteria would be set in stone, but in fact unlike diagnosing a broken bone, diagnosing diabetes presents a moving target—one that has been growing larger and easier to hit for many years.

The American Diabetes Association met in 1997 to discuss these criteria. Before the meeting, 21.6 million Americans had diabetes.

After the meeting, 25.5 million did.

All that was done was to lower the threshold that defined diabetes from a fasting blood glucose level of 140 mg/dl down to 125 mg/dl. That's an amazingly simple way to drum up business—create more sick people, not by making them sick but by redefining what it means to be healthy. When the meeting adjourned, 3.9 million unsuspecting Americans didn't suddenly go into diabetic shock; but perhaps some or many of them went to the doctor for a check-up and were shocked to learn that while last week they were OK, this week they have a chronic disease.

Six years later they did it again, only this time they lowered the threshold for diagnosing pre-diabetes, moving it from 110-125 mg/dl to 100-125 mg/dl. In 1997 they created almost four million new diabetics, but in 2003 they outdid themselves, creating 46.1 million new pre-diabetics who would be told that they are at high risk of developing type-2 diabetes. Remember this.

The New Drugs

Since 2004, the US FDA has approved 30 drugs for the treatment of people with type 2 diabetes. Most drugs take anywhere from 12-15 years to go from 'the bench to the bedside', so it's fair to assume that all of these drugs began their development somewhere around 1990 or after.

Of those 30 new drugs, how many of them are approved for pre-diabetes?

None. In fact there are no drugs approved to treat pre-diabetes. The reason for this is simple: Because there is not a shred of data supporting the use of these drugs in these patients. There is no proof that people with pre-diabetes who use these drugs will live longer or experience improved health outcomes. Patients who have taken the drugs do not demonstrate a reduced risk of developing the kinds of problems seen in people with diabetes, such as heart attacks, blindness, or amputations.

Despite the dearth of any evidence whatsoever, both the ADA and the AACE made recommendations in recent years saying that people with pre-diabetes could successfully be treated with drugs designed for people with diabetes.

Remember those 46.1 million Americans who, overnight, could be diagnosed with pre-diabetes? These experts were now telling Americans that they shouldn't let the fact that they do not have type 2 diabetes prevent them from taking drugs designed and approved for people with type 2 diabetes.

To make matters worse, the investigation uncovered the fact that since 2004, the newly approved FDA drugs for diabetes are considered the primary suspects in the deaths of 3,300 patients, and have sent another 20,000 to the hospital.*

The most egregious among these drugs are:

  • Byetta (exenatide)
  • Januvia (sitagliptin phosphate)
  • Victoza (liraglutide)
  • Janumet (sitagliptin + metformin)
  • Levemir (insulin detemir)
  • Onglyza (saxagliptin)

Read the full special report published by MedPage Today and the Milwaukee Journal Sentinel here: The Slippery Slope: A Bittersweet Diabetes Economy by John Fauber, Elbert Chu and Coulter Jones.

*You can find a full listing of adverse events from these drugs at MedPage Today's 5 Takeaways from the Diabetes Drugs Investigation.

Get a Free Diabetes Meal Plan

Get a free 7-Day Diabetes Meal Plan from Constance Brown-Riggs who is a Registered Dietitian-Certified Diabetes Educator and who is also a national spokesperson for the American Dietetic Association.

Just enter in your email below to download your free Diabetes Meal Plan.

By clicking Submit, you agree to send your info to BattleDiabetes.com who, in addition to 3rd party partners, may contact you with updates, products and information and we agree to use it according to our privacy policy and terms and conditions.

More Articles

More Articles

Tinnitus is a common condition affecting around 50 million adults in the U.S. It's defined as a "ringing in the ears" that can lead to difficulty...

It's important to follow a healthy diet if you have diabetes. Maintaining a frequent and nutritious eating schedule helps stabilize blood sugar...

Insulin resistance occurs when insulin is produced by the body but not used effectively by the cells....

Fainting, also called syncope, results from a temporary insufficiency in the supply of blood to the brain. Syncope can be the result of many...

Extreme hypoglycemia, with sugar levels under 70 mg/dl, is referred to as diabetic shock. It is a medical emergency. Persons with diabetes should...

Two kinds of edema are associated with diabetes: peripheral edema and diabetic macular edema. Peripheral edema is swelling in your lower legs,...

Diabetic test strips are one of the biggest expenses in diabetes care. People who are on a fixed income need to watch every penny that they spend...

Eating a balanced diet can have a significant impact on individuals who have type 2 diabetes. In fact,...

According to the Mayo Clinic, excessive alcohol consumption can increase a person's risk of developing type 2...

Many cultures use rice as a staple in their diet, and it is almost always white rice. If you order a burrito in a restaurant, you will probably...

With diabetes, your blood sugar levels...

Diabetic supplies are usually free or inexpensive for most people with insurance, but for uninsured or under-insured diabetics, they may be a bit...

Diabetics are prone to foot problems. Their feet often have poor circulation, and...

It is common knowledge that people with (or without) diabetes should exercise regularly. But why is exercise so important if diet appears to be...

Diabetes can be deadly if left undiagnosed, so it is very important to pay attention to your body if you are displaying any of the symptoms. Early...